This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Hansen Medical's CEO Presents At JP Morgan Healthcare Conference (Transcript)

We’ve also got a significant installed base of robotics systems in electrophysiology market. We’ve shipped 104 systems through September of 2011. And we are shipping more systems every quarter.

We’re also very excited about a new opportunity for the company in the, Vascular space. We’ve recently got a CE mark approval for our vascular robot which we call the Magellan System. In Europe, in Q4, we have placed our first system, we’ve got clinical cases coming out of that first system as well and we’ll talk much more about that in a few minutes.

And lastly, we continue to invest heavily in R&D. We believe our pipeline is very important to our future success, we are developing products for use with those two robotic systems and we have a – what we believe a game changing shape sensing technology which we call FOSSL for improved visualization of catheters used in minimally invasive procedures and again, we’ll talk more about that in just a minute.

So, the company was founded in 2002. We’ll celebrate our 10 th anniversary this year. Since that time, we’ve achieved a number of significant accomplishments which we believe that positions us well to be the leader of – in the flexible robotic space. You don't change the way medicine is practiced relative to medical robotics without a lot of good partnerships and we have several of them.

On the capital side, we’ve got partnerships with Philips and GE and Siemens. On the intellectual property and products side, partnerships with Intuitive Surgical, we have an important cross-license from them to some patents and run (ph) technology on our FOSSL.

2011 was a very good year for us. We continue to improve and grow our electrophysiology business in 2011. Obviously we got our Magellan System launched in Europe and towards the end of the year. And in the early part of the year, we signed an important license agreement with Philips Healthcare, relative to the shape sensing technology and we’ll talk more about that in a minute as well.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,528.03 -114.98 -0.69%
S&P 500 1,972.18 -16.69 -0.84%
NASDAQ 4,776.5080 -51.8170 -1.07%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs